Dual specificity mitogen-activated protein kinase kinase 2 is an enzyme that in humans is encoded by the MAP2K2 gene. [5] . It is more commonly known as MEK2, but has many alternative names including CFC4, MKK2, MAPKK2 and PRKMK2. [6] The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family.

Sep 24, 2015 · New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing...

MEK2 is a critical modulating mechanism to down-regulate GCIP stability and function in cancer cells. USP21-mediated deubiquitination and stabilization of MEK2 plays a critical role in hepatocellular carcinoma development.

Nov 14, 2004 · Here we present the X-ray structures of human MEK1 and MEK2, each determined as a ternary complex with MgATP and an inhibitor to a resolution of 2.4 Å and 3.2 Å, respectively. The structures...

Jan 6, 2012 · MEK1 and MEK2 are related protein kinases that participate in the RAS-RAF-MEK-ERK signal transduction cascade. This cascade participates in the regulation of a large variety of processes including apoptosis, cell cycle progression, cell migration, differentiation, metabolism, and proliferation.

New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity.

Dec 25, 2024 · MAP2K2 (Mitogen-Activated Protein Kinase Kinase 2) is a Protein Coding gene. Diseases associated with MAP2K2 include Cardiofaciocutaneous Syndrome 4 and Cardiofaciocutaneous Syndrome. Among its related pathways are Prolactin Signaling and IL-9 Signaling Pathways.

This demonstrates the pivotal roles of MEK1/2 in malignant transformation, rationalizing therapeutic targeting of upregulated MEK1/2 activity in cancer. In addition, there are unique characteristics of MEK1 and MEK2 that might support the advantage of therapeutic development of MEK1/2 inhibition.

Aug 7, 2018 · MAPK/ERK kinase (MEK) 1/2 are central signaling proteins that serve as specificity determinants of the MAPK/ERK cascade. More than twenty activating mutations have been reported for MEK1/2,...

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma.